# Clinical Trials Data ERBB2 - Document 36

# HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598

## Clinical Trial: https://clinicaltrials.gov/study/NCT00896909

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of non-small cell lung cancer meeting \u2265 1 of the following criteria:\n\n \* Recurrent disease\n \* Stage IIIB with pleural or pericardial effusion\n \* Stage IV disease\n\* Treated on protocol ECOG-2598\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
This trial description \*\*does not mention ERBB2 gene mutation status\*\* as an inclusion or exclusion criterion. Therefore, based on the information provided, we \*\*cannot determine\*\* if a patient with an ERBB2 mutation would be eligible. The criteria focus on disease stage and prior treatment (specifically, participation in the ECOG-2598 protocol).   
  
The patient \*might\* be eligible if they meet the disease characteristics and prior therapy requirements, but more information about the trial's inclusion/exclusion criteria related to specific gene mutations is needed for a definitive answer.